The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat early symptomatic Alzheimer's disease, drugmaker Eli Lilly said. The move ...
The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments. Scientists focused on amyloid-β (Aβ) plaques and tau aggregates to slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback